ReviewBehavioural brain research2020
Ketamine and rapid acting antidepressants: Are we ready to cure, rather than treat depression?
Review in Behavioural brain research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Enhancing plasticity to treat depression and other central nervous system diseases using event-driven pharmacology.Journal of psychopharmacology (Oxford, England) · 2026Review
- Opioid use disorder: current trends and potential treatments.Frontiers in public health · 2023Review
- Imaging synaptic density in depression.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2023Review
- A unique case of very low-dose subcutaneous ketamine use: Maintenance option of ketamine for treatment-resistant depression.Clinical case reports · 2022Article
- The effects of social isolation stress and discrimination on mental health.Translational psychiatry · 2022Review
- Rapid-acting and long-lasting antidepressant-like action of (R)-ketamine in Nrf2 knock-out mice: a role of TrkB signaling.European archives of psychiatry and clinical neuroscience · 2021Article
- Ketamine: A tale of two enantiomers.Journal of psychopharmacology (Oxford, England) · 2021Review
- Repurposing Ketamine in Depression and Related Disorders: Can This Enigmatic Drug Achieve Success?Frontiers in neuroscience · 2021Review
- Ketamine beyond anesthesia: Antidepressant effects and abuse potential.Behavioural brain research · 2020Article
- Brain Networks Associated With COVID-19 Risk: Data From 3662 Participants.Chronic stress (Thousand Oaks, Calif.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Depression is a leading cause of disability, with often chronic course of illness and high treatment resistance in a large proportion of patients. In the current short perspective paper, we present evidence supporting the presence of synaptic-based chronic stress pathology (CSP) in depression and across a number of psychiatric disorders. We summarize the synaptic connectivity model of CSP, and briefly review related preclinical and clinical evidence, while providing appropriate references for more comprehensive reviews and alternative models. We then underscore some gaps in the literature and provide various tips for future directions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.